Try our Advanced Search for more refined results
IN RE SANOFI SECURITIES LITIGATION
Case Number:
1:13-cv-08806
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Sectors & Industries:
-
January 28, 2015
Fraud Suits Targeting Sanofi Over MS Drug Prospects Tossed
A Manhattan federal judge on Tuesday threw out an investor class action and a related securities fraud damages suit against Sanofi over a 2013 setback in its effort alongside recently acquired Genzyme Corp. to win approval for their Lemtrada multiple sclerosis drug, finding rosy statements predicting on-time approval were genuinely believed when they were made.
-
October 31, 2014
Sanofi's Duty To Detail FDA Concerns Key To Lemtrada Cases
A New York federal judge asked Friday whether Sanofi's "very happy opinion" shared with investors about prospects for on-time approval of its potential blockbuster Lemtrada multiple sclerosis drug carried with it a duty to detail concerns among regulators about bias in the single-blind method by which the drug giant and its recently acquired Genzyme Corp. unit were conducting trials.